Latest Content

The phase 3 SigVie-002 trial showed sigvotatug vedotin missed the OS end point, but the second-line subgroup showed a survival trend and manageable safety.

FDA approval of generic rifapentine introduces a new option for treating active tuberculosis and preventing progression of latent infection.

Joseph K. Han, MD, discusses upstream biologics, verekitug, and the future of chronic rhinosinusitis with nasal polyps treatment.

Patients with familial pulmonary fibrosis had faster FVC decline and were more likely to have a UIP pattern, supporting family history as a prognostic tool.

With an FDA approval for its companion diagnostic in bladder cancer, Natera extends its Treatment on MRD strategy, deferring adjuvant immunotherapy for patients with negative results for disease following surgery.

Structured CHE diagnosis improves outcomes: a multicenter CRF clarifies causes for most patients with chronic hand eczema, addressing diagnosis challenges and guiding targeted care.

Adults with obesity using an AI-CGM platform lost weight nearly 3 times faster during engaged vs nonengaged periods (1.17% vs 0.44% per week).

Real-world data show AI coaching plus CGM helps adults with obesity lose up to 7% in 6 months, with engagement driving faster weekly weight loss.

EXTEND trial data show nurse-delivered telehealth for type 2 diabetes missed its primary end point in fee-for-service care, raising questions about reimbursement.